62 related articles for article (PubMed ID: 25315075)
1. A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma.
Demajo S; Albero R; Clot G; Castellano G; Navarro A; Capdevila C; Enjuanes A; Nadeu F; Giné E; Pinyol M; Jaffe ES; Ott G; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; López-Guillermo A; Beà S; Campo E; Jares P
Clin Cancer Res; 2021 Jan; 27(1):213-225. PubMed ID: 33046520
[TBL] [Abstract][Full Text] [Related]
2. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma.
Wang JD; Katz SG; Morgan EA; Yang DT; Pan X; Xu ML
Hum Pathol; 2019 Nov; 93():54-64. PubMed ID: 31425695
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.
Pieters T; T'Sas S; Vanhee S; Almeida A; Driege Y; Roels J; Van Loocke W; Daneels W; Baens M; Marchand A; Van Trimpont M; Matthijssens F; Morscio J; Lemeire K; Lintermans B; Reunes L; Chaltin P; Offner F; Van Dorpe J; Hochepied T; Berx G; Beyaert R; Staal J; Van Vlierberghe P; Goossens S
J Exp Med; 2021 Oct; 218(10):. PubMed ID: 34406363
[TBL] [Abstract][Full Text] [Related]
4. Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status.
Hassan HM; Varney ML; Chaturvedi NK; Joshi SS; Weisenburger DD; Singh RK; Dave BJ
Leuk Lymphoma; 2016 Dec; 57(12):2874-2889. PubMed ID: 27074052
[TBL] [Abstract][Full Text] [Related]
5. Novel targeted therapies for mantle cell lymphoma.
Alinari L; Christian B; Baiocchi RA
Oncotarget; 2012 Feb; 3(2):203-11. PubMed ID: 22361516
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
Kim DH; Siddiqui S; Jain P; Wang M; Thakral B; Li S; Miranda R; Vega F; Medeiros LJ; Ok CY
Hum Pathol; 2024 Apr; 146():1-7. PubMed ID: 38460798
[TBL] [Abstract][Full Text] [Related]
7. Suppression of cancer cell growth by promoting cyclin D1 degradation.
Shan J; Zhao W; Gu W
Mol Cell; 2009 Nov; 36(3):469-76. PubMed ID: 19917254
[TBL] [Abstract][Full Text] [Related]
8. Leukemic non-nodal cyclin D1- and SOX11-negative mantle cell lymphoma with CCND3::IGH rearrangement.
Tan L; Bansal G; Yeung CC; Yin J; Dave BJ; Konnick E; Wu D; Naresh KN
Ann Hematol; 2024 Feb; 103(2):667-669. PubMed ID: 37882866
[No Abstract] [Full Text] [Related]
9. A Pancreatic Collision Tumor Comprising Mantle Cell Lymphoma and Adenocarcinoma: A Case Report and Literature Review.
Sugaya R; Taniguchi A; Abe M; Ozawa I; Kirito K; Hatakeyama S
Intern Med; 2024 Feb; 63(4):553-558. PubMed ID: 37380453
[TBL] [Abstract][Full Text] [Related]
10. A peculiar case of cyclin D1-positive lymphoplasmacytic lymphoma.
Luu BE; Xu SA
Blood; 2023 Dec; 142(23):2034. PubMed ID: 38060270
[No Abstract] [Full Text] [Related]
11. Risk factors for etiology and prognosis of mantle cell lymphoma.
Wang Y; Ma S
Expert Rev Hematol; 2014 Apr; 7(2):233-43. PubMed ID: 24559208
[TBL] [Abstract][Full Text] [Related]
12. Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma.
Lymphoma Research Foundation LRF
Oncology (Williston Park); 2024 Feb; 38(2):51-67. PubMed ID: 38421601
[TBL] [Abstract][Full Text] [Related]
13. Takes one to B1a: Dismantling the origin of mantle cell lymphoma.
Beaudin AE
J Exp Med; 2021 Oct; 218(10):. PubMed ID: 34529750
[TBL] [Abstract][Full Text] [Related]
14. New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?
Dreyling M; Ferrero S; Vogt N; Klapper W;
Clin Cancer Res; 2014 Oct; 20(20):5194-206. PubMed ID: 25320369
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection.
Fogli LK; Williams ME; Connors JM; Reid Y; Brown K; O'Connor OA
Leuk Lymphoma; 2015 Jul; 56(7):2114-22. PubMed ID: 25315077
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis.
Baumann U; Fernández-Sáiz V; Rudelius M; Lemeer S; Rad R; Knorn AM; Slawska J; Engel K; Jeremias I; Li Z; Tomiatti V; Illert AL; Targosz BS; Braun M; Perner S; Leitges M; Klapper W; Dreyling M; Miething C; Lenz G; Rosenwald A; Peschel C; Keller U; Kuster B; Bassermann F
Nat Med; 2014 Dec; 20(12):1401-9. PubMed ID: 25419709
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
Bernard S; Danglade D; Gardano L; Laguillier C; Lazarian G; Roger C; Thieblemont C; Marzec J; Gribben J; Cymbalista F; Varin-Blank N; Ledoux D; Baran-Marszak F
Int J Cancer; 2015 Jun; 136(12):2761-74. PubMed ID: 25388373
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib for the treatment of mantle cell lymphoma.
Herrera AF; Jacobsen ED
Clin Cancer Res; 2014 Nov; 20(21):5365-71. PubMed ID: 25361916
[TBL] [Abstract][Full Text] [Related]
19. No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.
Vogt N; Abramov D; Koch K; Masqué-Soler N; Szczepanowski M; Klapper W
Leuk Lymphoma; 2015 Jul; 56(7):2134-40. PubMed ID: 25315075
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
